Staff perspectives on facilitating the implementation of hepatitis C services at drug treatment programs

Journal of Psychoactive Drugs

Volumn 38, Issue 3, 2006, Pages 233-241

  Munoz Plaza, Corrine E ^a   Strauss, Shiela M ^a   Astone Twerwll, Janetta M ^a   Des Jarlais, Don C ^b   Hagan, Holly ^c  

^a STOP HEP C Project   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Drug treatment programs; Education; Hepatitis C

Indexed keywords

ARTICLE; DRUG DEPENDENCE TREATMENT; FUNDING; HEALTH CARE DELIVERY; HEALTH EDUCATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; METHADONE TREATMENT; OUTPATIENT CARE; RESPONSIBILITY; STAFF TRAINING; SUPPORT GROUP;

EID: 33751070476     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2006.10399849     Document Type: Article

References (45)

1. Alter, M.J. & Moyer, L.A. 1998. The importance of preventing hepatitis C virus infection among injection drug users in the United States. Journal of Acquired Immune Deficiency Syndrome 18: S6-S10.
2. Alter, M.J.; Kruszon-Moran, D.; Nainan, O.V.; McQuillan, G.M.; Goa, F.; Moyer, L.A.; Kaslow, R.A. & Margolis, H.S. 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine 341: 556-62.
3. Astone, J.; Strauss, S.; Hagan, H. & Des Jarlais, D. 2004. Outpatient drug treatment program directors' hepatitis-C related beliefs and their relationship to the provision of HCV services. American Journal of Drug and Alcohol Abuse 30 (4): 783-97.
4. Astone, J.; Strauss, S.; Vassilev, Z. & Des Jarlais, D. 2003. Provision of hepatitis C education in a nationwide sample of drug treatment programs. Journal of Drug Education 33 (1): 107-17.
5. Bae, J.P. 1997. Assessing the need, use, and developments in mental health/substance abuse care. Health Care Finance 18: 1-4.
6. Best, D.; Noble, A.; Finch, E.; Gossop, M.; Sidwell, C. & Strang, J. 1999. Accuracy of perceptions of hepatitis B andC status: Cross sectional investigation of opiate addicts in treatment. British Medical Journal 319: 290-91.
7. Centers for Disease Control and Prevention (CDC). 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morbidity and Mortality Weekly Report 41 (RR-19): 1-39.
8. Chi-Chi, N; Pratt, U.; Paone, D.; Carter, R. & Layton, M. 2002. Hepatitis C screening and management practices: A survey of drug treatment and syringe exchange programs in New York City. Research and Practice 92 (8): 1254-56.
9. Chitwood, D.; McBride, D.; French, M. & Comerford, M. 1999. Health care need and utilization: A preliminary comparison of injection drug users, other illicit drug users, and nonusers. Substance Use and Misuse 34: 727-46.
10. Contoreggi, C.; Rexroad, V. & Lange, W. 1998. Current management of infectious complications in the injecting drug user. Journal of Substance Abuse Treatment 15: 95-106.
11. D'Aunno, T. & Vaughn, T. 1995. An organizational analysis of service patterns in outpatient drug abuse treatment units. Journal of Substance Abuse 7 (1): 27-42.
12. D'Aunno, T.; Vaughn, T. & McElroy, P. 1999. An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units. Journal of Health and Social Behavior 40: 175-92.
13. Des Jarlais, D. 1990. Stages in the response of the drug abuse treatment system to the AIDS epidemic in New York City. Journal of Drug Issues 20 (2): 335-47.
14. Des Jarlais, D. & Schuchat, A. 2001. Hepatitis C among drug users: Déjà vu all over again? American Journal of Public Health 91 (1): 21-2.
15. Dhopesh, V.P.; Taylor, K.R. & Burke, W.M. 2000. Survey of hepatitis B and C in addiction treatment unit. American Journal of Drug and Alcohol Abuse 26 (4): 703-07.
16. Edlin, B.R. 2004. Hepatitis C prevention and treatment for substance users in the United States: Acknowledging the elephant in the living room. International Journal of Drug Policy 15: 81-91.
17. Edlin, B.R. 2002. Prevention and treatment of hepatitis C in injection drug users. Hepatology 36 (5) (Suppl 1): S210-l9.
18. Etheridge, R.M.; Craddock, S.G.; Dunteman, G.H. & Hubbard, R.L. 1995. Treatment services in two national studies of community-based drug abuse treatment programs. Journal of Substance Abuse 7 (1): 9-26.
19. Garfein, R.S.; Doherty, M.C.; Monterroso, E.R.; Thomas, D.L.; Nelson, K.E. & Vlahov, D. 1998. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 18 (Suppl. 1): S11-S 19.
20. Hagan H.; McGough, J.P.; Thiede, H.; Weiss, N.S.; Hopkins, S. & Alexander, E.R. 1999. Syringe exchange and risk of infection with hepatitis B and C viruses. American Journal of Epidemiology 149 (3): 203-13.
21. Hagan, H.; Thiede, H.; Weiss, H.S.; Hopkins, S.G.; Duchin, J.S. & Alexander, E.R. 200l. Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health 91: 42-46.
22. Kwiatkowski, C.F.; Fortuin, E.; Corsi, K. & Booth, R.E. 2002. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 97: 1289-94.
23. Lee, M.; Reif, S.; Ritter, G.; Levine, H. & Horgan, C. 2001. Access to services in the substance abuse treatment system: Variations in facility characteristics. In: M. Galanter (Ed.) Recent Developments in Alcoholism, Volume 15: Services Research in the Era of Managed Care. London: Kluwer Academic/Plenum Publishers.
24. Liang, T.J.; Rehermann, B.; Seeff, L.B. & Hoofnagle, J.H. 2000. Pathogenisis, natural history, treatment, and prevention of hepatitis C. Annals of Internal Medicine 132 (4): 296-305.
25. Lorvick, J.; Kral, A.H.; Seal, K.H.; Gee, L. & Edlin, B.R. 2001. Prevalence and duration of hepatitis C among injection drug users in San F^ocisco, American Journal of Public Health 91: 46-47.
26. Munoz-Plaza, C.; Strauss, S.; Astone, J.; Des Jarlais, D. & Hagan, H. 2004. Drug treatment programs as sites of opportunity for the delivery of hepatitis C prevention education: Client and staff perspectives. Journal of Drug Issues 34 (4): 861-78.
27. National Institutes of Health. 2002. Management of hepatitis C: 2002. NIH Consensus and State-of-the-Science Statements 19 (3): 1-46. Available from http://consensus.nih.gov
28. Pratt, C.; Paone, D.; Carter, B. & Layton, M. 2002. Hepatitis C screening and management practices: A survey of drug treatment and syringe exchange programs in New York City. American Journal of Public Health 92: 1254-56.
29. Pugatch, D.; Levesque, B.; Greene, S.; Strong, L.; Flanigan, T. & Lally, M. 200l. HIV testing in the setting of inpatient acute substance abuse treatment. American Journal of Drug and Alcohol Abuse 27 (3): 491-99.
30. Rosenblum, A.; Nuttbrock, L.; McQuistion, H.; Magura, S. & Joseph, H. 2001. Hepatitis C and substance use in a sample of homeless people in New York City. Journal of Addictive Diseases 20 (4): 15-25.
31. Selwyn, P.A.; Budner, N.S.; Wasserman, W.C. & Arno, P.S. 1993. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Reports 108 (4): 492-500.
32. Shehab, T.; Sonnad, S. & Lok, A. 2001. Management of hepatitis C by primary care physicians in the USA: Results of a national survey. Journal of Viral Hepatitis 8: 377-83.
33. Sorenson, J. 1991. Preventing HIV transmission in drug treatment prograis: What works? Jourrnal of Addictive Diseases 10 (4): 67-79.
34. Sorensen, J.; Masson, C. & Perlman, D. 2002. HIV/hepatitis prevention in drug abuse treatment programs: Guidance from research. Science & Practice Perspectives (July): 4-12.
35. Stein, M.D.; Maksad, J. & Clarke, J. 2001. Hepatitis C disease among injection drug users: Knowledge, perceived risk and willingness to receive treatment. Drug and Alcohol Dependence 61: 211-15.
36. Strauss, S.; Astone, J.; Des Jarlais, D. & Hagan, H. 2004a. Integrating hepatitis C services into existing HIV services: The experience of a sample ofU.S. drug treatment units. AIDSPatient Care and STDs 19 (2): 78-88.
37. Strauss, S.;Astone, J.; Des Jarlais, D. & Hagan, H. 2004b. A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. Drug and Alcohol Dependence 73: 227-36.
38. Strauss, S.; Astone, J; Hagan, H. & Des Jarlais, D. 2004c. The content and comprehensiveness of hepatitis C education in methadone maintenanceand drug-free treatment units. Jourrnal of Urban Health 81: 38-47.
39. Strauss, S.M.; Astone, J.; Vassilev, Z.P.; Des Jarlais, D. & Hagan, H. 2003a. Gaps in the drug-free and methadone treatment program response to hepatitis C. Journal of Substance Abuse Treatment 24: 291-97.
40. Strauss, S.; Des Jarlais, D.; Astone, J. & Vassilev, Z. 2003b. On-site HIV testing in residential drug treatment units: Results of a nationwide survey. Public Health Reports 118: 37-43.
41. Strauss, S.; Falkin, G.; Vassilev, Z.; Des Jarlais, D. & Astone, J. 2002. A nationwide survey of hepatitis C services provided by drug treatment programs. Journil of Substance Abuse Treatment 22: 55-62.
42. Thomas D.L.; Vlahov, D.; Solomon, L.; Cohn, S.; Taylor, E.; Garfein, R. & Nelson, K.E. 1995. Correlates of hepatitis C virus infections among injection drug users. Medicine 74 (4): 212-20.
43. Tortu, S.; Neaigus, A.; McMahon, J. & Hagen, D. 2001. Hepatitis C among non-injecting drug users: A report. Substance Use and Misuse 36: 523-34.
44. Winstock, A.; Sheridan, S.; Lovell, M. & Strang, J. 2000 National survey of hepatitis testing and vaccination services provided by drug services in England and Wales. European Journal of Clinical Microbiology & Infectious Diseases 19: 823-28.
45. World Health Organization. 2000. Hepatitis C: Global prevalence. Weekly Epidemiological Record 3: 18-19.